Scarica l'app Stockscreener
3.90
0.78%
0.03
Dopo l'orario di chiusura:
3.98
0.08
+2.05%
C 4 Therapeutics Inc Borsa (CCCC) Ultime notizie
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
C4 Therapeutics reports updated cemsidomide data at EHA 2026 - grafa.com
C4 Therapeutics Presents Phase 1 Data at European Hematology Association 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population - Investing News Network
C4 Therapeutics presents cemsidomide data at EHA congress - Investing.com UK
C4 Therapeutics presents cemsidomide data at EHA congress By Investing.com - Investing.com Australia
C4 Therapeutics (CCCC) Unveils Phase 1 Trial Insights on Cemsido - GuruFocus
C4 Therapeutics Reports 53% Response Rate for Cemsidomide at RP2D - marketscreener.com
C4 Therapeutics Highlights Cemsidomide Strategy and Trial Progress - TipRanks
C4 Therapeutics posts Phase 1 cemsidomide data and corporate presentation ahead of EHA 2026 - TradingView
C4 Therapeutics (NASDAQ: CCCC) highlights cemsidomide Phase 1 response rates in RRMM - Stock Titan
C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population - The Manila Times
Heavily pretreated myeloma patients see durable responses on C4 oral therapy - Stock Titan
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Caledonian Record
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Intellia Therapeutics
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Director Anderson (NASDAQ: CCCC) exercises 1,070 options at $2.11 - Stock Titan
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Abeona Therapeutics (ABEO) details FDA Pre-IND meeting and 2027 IND goal for ABO-701 - Stock Titan
Viking Therapeutics (NASDAQ: VKTX) CMO awarded 190,000 stock options - Stock Titan
Viking Therapeutics (NASDAQ: VKTX) Chief Medical Officer named insider in Form 3 filing - Stock Titan
Executive team at C4 Therapeutics, Inc. set for Jefferies conference fireside chat - Traders Union
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - Yahoo Finance
C4 Therapeutics, Inc. (CCCC) reports Q1 loss, lags revenue estimates - MSN
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Caledonian Record
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Caledonian Record
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics 'Buy' On Cemsidomide Advancement And Competitor's Positive Readout (CCCC) - Seeking Alpha
Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026 - PR Newswire
C4 Therapeutics' Cemsidomide: A Foundational Treatment Across Multiple Lines Of Multiple Myeloma? - RTTNews
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Karyopharm
C4 Therapeutics (CCCC) upgraded to buy: What does it mean for the stock? - MSN
C4 Therapeutics (CCCC) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
C4 Therapeutics (CCCC) Hits 52-Week High Following BMY Trial Suc - GuruFocus
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
C4 Therapeutics (CCCC) Hits 52-Week High Following BMY Trial Success - GuruFocus
CCCC (NASDAQ) insider exercise-and-sale: 9,087 options sold from 29,080 grant - Stock Titan
CCCC: Cemsidomide demonstrates robust late-line efficacy and safety, with global expansion and new combinations planned - TradingView
Are medical stocks lagging C4 Therapeutics (CCCC) this year? - MSN
Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Caledonian Record
Clinical trial participation drives development of innovative treatments, C4 Therapeutics, Inc. - Traders Union
C4 Therapeutics to Participate in Upcoming Conferences - Investing News Network
1.04%
0.76%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):